FASN and metabolic dysfunction-associated steatohepatitis: The effect of FASN inhibition was also evaluated in a therapeutic model of diet-induced NASH with CCl4 administration to cause liver fibrosis, recently termed the FAT (Fibrosis And Tumors)-NASH model29.